Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a research report sent to investors on Thursday.

Several other analysts have also commented on the stock. Oppenheimer upgraded shares of Ascendis Pharma A/S from a market perform rating to an outperform rating and set a $180.00 price objective for the company in a report on Thursday. Cantor Fitzgerald reduced their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating for the company in a research report on Wednesday, September 4th. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a buy rating and a $200.00 target price for the company. Jefferies Financial Group lifted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. Finally, Wells Fargo & Company dropped their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research note on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of Moderate Buy and an average target price of $187.08.

Ascendis Pharma A/S Trading Up 0.1 %

Shares of NASDAQ:ASND opened at $119.15 on Thursday. The stock’s 50-day moving average price is $134.38 and its 200-day moving average price is $137.94. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The stock has a market capitalization of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 1.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after purchasing an additional 44,580 shares during the period. Capital International Investors boosted its stake in Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD raised its position in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after buying an additional 93,185 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.